Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
ADMA · Nasdaq · United States · Biological Products, (No Diagnostic Substances)
In shortADMA BIOLOGICS, INC. is profitable, generates cash and holds more cash than debt, with revenue growing (+19.6% last year).
Financial health
Solid
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 37.5% | 100/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 28.8% | 100/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 35.6% | 100/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 28.0% | 100/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 6.71× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.15× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 26.93× | 100/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 8.80 | 100/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 5.5% | 42/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 0.19× | 0/100 |
| Years with positive free cash flow (last 5) | 3 of 5 | 50/100 |
Weight in the score: 20%
| Profitable years (last 5) | 2 of 5 | 40/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 29.2% | 3/100 |
| Operating margin volatility | 45.6% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 49.0% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 81 | 154 | 258 | 426 | 510 |
| Cost of revenue | 80 | 119 | 169 | 207 | 217 |
| Gross profit | 1.2 | 35 | 89 | 220 | 293 |
| Research & development | 3.6 | 3.6 | 3.3 | 1.8 | 4.8 |
| Selling, general & admin | 43 | 52 | 59 | 74 | 92 |
| Operating income | (58) | (39) | 22 | 139 | 191 |
| Interest expense | 13 | 19 | 25 | 14 | 7.1 |
| Pre-tax income | – | (66) | (28) | 126 | 183 |
| Income tax | 0 | 0 | 0 | (72) | 36 |
| Net income | (72) | (66) | (28) | 198 | 147 |
| Diluted EPS | −$0.51 | −$0.33 | −$0.13 | $0.81 | $0.60 |
| Diluted shares (millions) | 140 | 198 | 224 | 243 | 245 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 8 reported quarters (10-Q and 10-K filings), in USD millions. The fourth quarter is derived from the annual report.
The last 8 quarters of ADMA BIOLOGICS, INC. are included in the Investor plan. Try free for 7 days →
8.80 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
5/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 5, 2026